These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 36263321)

  • 1. New insight into the importance of formulation variables on parenteral growth hormone preparations: potential effect on the injection-site pain.
    Taghizadeh B; Jaafari MR; Zarghami N
    Front Endocrinol (Lausanne); 2022; 13():963336. PubMed ID: 36263321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid growth hormone: preservatives and buffers.
    Kappelgaard AM; Bojesen A; Skydsgaard K; Sjögren I; Laursen T
    Horm Res; 2004; 62 Suppl 3():98-103. PubMed ID: 15539807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous Injection Site Pain of Formulation Matrices.
    Shi GH; Pisupati K; Parker JG; Corvari VJ; Payne CD; Xu W; Collins DS; De Felippis MR
    Pharm Res; 2021 May; 38(5):779-793. PubMed ID: 33942212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Systematic Literature Review of Injection Site Pain Perception in Adult Patients Treated with Citrate-Free and Citrate-Containing Biologic Agents.
    Junker S; Ebert O; Bartsch R
    Curr Rheumatol Rev; 2023 Jun; 19(3):303-313. PubMed ID: 36043729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site.
    Usach I; Martinez R; Festini T; Peris JE
    Adv Ther; 2019 Nov; 36(11):2986-2996. PubMed ID: 31587143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review.
    St Clair-Jones A; Prignano F; Goncalves J; Paul M; Sewerin P
    Rheumatol Ther; 2020 Dec; 7(4):741-757. PubMed ID: 33206343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excipient exchange in the comparison of preparations of the same biologic made by different manufacturing processes: an exploratory study with recombinant human growth hormone (rhGH).
    Cauchy M; Hefford MA
    Biologicals; 2010 Nov; 38(6):637-43. PubMed ID: 20797874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of Formulations of Commercially Available Antibodies.
    Strickley RG; Lambert WJ
    J Pharm Sci; 2021 Jul; 110(7):2590-2608.e56. PubMed ID: 33789155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Excipient-drug interactions in parenteral formulations.
    Akers MJ
    J Pharm Sci; 2002 Nov; 91(11):2283-300. PubMed ID: 12379914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Acting Growth Hormone Preparations in the Treatment of Children.
    Lal RA; Hoffman AR
    Pediatr Endocrinol Rev; 2018 Sep; 16(Suppl 1):162-167. PubMed ID: 30378794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Acting Growth Hormone: An Update.
    Saenger PH; Mejia-Corletto J
    Endocr Dev; 2016; 30():79-97. PubMed ID: 26683877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel sustained-release formulation of recombinant human growth hormone and its pharmacokinetic, pharmacodynamic and safety profiles.
    Wei Y; Wang Y; Kang A; Wang W; Ho SV; Gao J; Ma G; Su Z
    Mol Pharm; 2012 Jul; 9(7):2039-48. PubMed ID: 22663348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ease of use and preference for a new disposable self-injection pen compared with a reusable pen for administering recombinant human growth hormone: A multicenter, 2-month, single-arm, open-label clinical trial in patient-caregiver dyads.
    Hey-Hadavi J; Pleil A; Deeb LC; Fuqua JS; Silverman LA; Reiner B; Newfield R; Rajicic N; Wajnrajch MP; Cara JF
    Clin Ther; 2010 Nov; 32(12):2036-47. PubMed ID: 21118739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stable formulations of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable microspheres.
    Cleland JL; Jones AJ
    Pharm Res; 1996 Oct; 13(10):1464-75. PubMed ID: 8899836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abuse of recombinant human growth hormone: studies in two different dog models.
    Rigamonti AE; Scanniffio D; Bonomo SM; Cella SG; Sartorio A; Müller EE
    Neuroendocrinology; 2004; 79(5):237-46. PubMed ID: 15218318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stabilization of recombinant human growth hormone against emulsification-induced aggregation by Pluronic surfactants during microencapsulation.
    Wei G; Lu LF; Lu WY
    Int J Pharm; 2007 Jun; 338(1-2):125-32. PubMed ID: 17336005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioequivalence studies for three formulations of a recombinant human growth hormone: challenges and lessons learned.
    Dao L; Jacobs J; Kuebler P; Bakker B; Lippe B
    Growth Horm IGF Res; 2010 Oct; 20(5):367-71. PubMed ID: 20708421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioequivalence between ready-to-use recombinant human growth hormone (rhGH) in liquid formulation and rhGH for reconstitution.
    Jacobsen LV; Rolan P; Christensen MS; Knudsen KM; Rasmussen MH
    Growth Horm IGF Res; 2000 Apr; 10(2):93-8. PubMed ID: 10931747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pain perception after subcutaneous injections of media containing different buffers.
    Laursen T; Hansen B; Fisker S
    Basic Clin Pharmacol Toxicol; 2006 Feb; 98(2):218-21. PubMed ID: 16445598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Adherence to Injectable Treatments in Pediatric Growth Hormone Deficiency Compared With Injectable Treatments in Other Chronic Pediatric Conditions: A Systematic Literature Review.
    Gomez R; Ahmed SF; Maghnie M; Li D; Tanaka T; Miller BS
    Front Endocrinol (Lausanne); 2022; 13():795224. PubMed ID: 35299969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.